204 related articles for article (PubMed ID: 29322659)
21. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.
Lawson R; King F; Marsh K; Altincatal A; Cimen A
Adv Ther; 2016 Aug; 33(8):1331-46. PubMed ID: 27342744
[TBL] [Abstract][Full Text] [Related]
22. Decision-making in drug development using a composite definition of success.
Saint-Hilary G; Robert V; Gasparini M
Pharm Stat; 2018 Sep; 17(5):555-569. PubMed ID: 29956453
[TBL] [Abstract][Full Text] [Related]
23. Naloxegol , a new drug for the treatment of opioid-induced constipation.
Corsetti M; Tack J
Expert Opin Pharmacother; 2015 Feb; 16(3):399-406. PubMed ID: 25496063
[TBL] [Abstract][Full Text] [Related]
24. Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation.
Al-Huniti N; Nielsen JC; Hutmacher MM; Lappalainen J; Cantagallo K; Sostek M
CPT Pharmacometrics Syst Pharmacol; 2016 Jul; 5(7):359-66. PubMed ID: 27435972
[TBL] [Abstract][Full Text] [Related]
25. Decision-making in product portfolios of pharmaceutical research and development--managing streams of innovation in highly regulated markets.
Jekunen A
Drug Des Devel Ther; 2014; 8():2009-16. PubMed ID: 25364229
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.
Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y
J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486
[TBL] [Abstract][Full Text] [Related]
27. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
Jones R; Prommer E; Backstedt D
Am J Hosp Palliat Care; 2016 Nov; 33(9):875-880. PubMed ID: 26150678
[TBL] [Abstract][Full Text] [Related]
28. ▼Naloxegol for opioid-induced constipation.
Drug Ther Bull; 2015 Dec; 53(12):138-40. PubMed ID: 26660436
[TBL] [Abstract][Full Text] [Related]
29. Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain.
Leonard J; Baker DE
Ann Pharmacother; 2015 Mar; 49(3):360-5. PubMed ID: 25471070
[TBL] [Abstract][Full Text] [Related]
30. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
[TBL] [Abstract][Full Text] [Related]
31. Model-based approaches for time-dependent dose finding with repeated binary data.
Benda N
Stat Med; 2010 May; 29(10):1096-106. PubMed ID: 20082362
[TBL] [Abstract][Full Text] [Related]
32. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
33. Naloxegol: a review of its use in patients with opioid-induced constipation.
Garnock-Jones KP
Drugs; 2015 Mar; 75(4):419-25. PubMed ID: 25666542
[TBL] [Abstract][Full Text] [Related]
34. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
Corsetti M; Tack J
Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
[TBL] [Abstract][Full Text] [Related]
35. Use of predictive probabilities in phase II and phase III clinical trials.
Johns D; Andersen JS
J Biopharm Stat; 1999 Mar; 9(1):67-79. PubMed ID: 10091910
[TBL] [Abstract][Full Text] [Related]
36. Application and Impact of Human Dose Projection from Discovery to Early Drug Development.
Patel D; Yang W; Lipert M; Wu T
AAPS PharmSciTech; 2020 Jan; 21(2):44. PubMed ID: 31897807
[TBL] [Abstract][Full Text] [Related]
37. Single-arm phase IIA clinical trials with go/no-go decisions.
Zhong B
Contemp Clin Trials; 2012 Nov; 33(6):1272-9. PubMed ID: 22796490
[TBL] [Abstract][Full Text] [Related]
38. Can a multiple ascending dose study serve as an informative proof-of-concept study?
Qu Y
Stat Med; 2019 Feb; 38(3):354-362. PubMed ID: 30264404
[TBL] [Abstract][Full Text] [Related]
39. Perspectives on the Role of Mathematics in Drug Discovery and Development.
Allen R; Moore H
Bull Math Biol; 2019 Sep; 81(9):3425-3435. PubMed ID: 30693431
[TBL] [Abstract][Full Text] [Related]
40. The clinical utility index as a practical multiattribute approach to drug development decisions.
Poland B; Hodge FL; Khan A; Clemen RT; Wagner JA; Dykstra K; Krishna R
Clin Pharmacol Ther; 2009 Jul; 86(1):105-8. PubMed ID: 19458614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]